AZD8154 is a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease.
[1]. Sadiq MW, et al. Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease. Br J Clin Pharmacol. 2021 Jun 28.
















